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The serine/threonine protein phosphatase 5 (PP5)
regulates multiple cellular signaling networks. A
number of cellular factors, including heat shock pro-
tein 90 (Hsp90), promote the activation of PP5. How-
ever, it is unclear whether post-translational modifi-
cations also influence PP5 phosphatase activity.
Here, we show an ‘‘on/off switch’’ mechanism for
PP5 regulation. The casein kinase 1d (CK1d) phos-
phorylates T362 in the catalytic domain of PP5, which
activates and enhances phosphatase activity inde-
pendent of Hsp90. Overexpression of the phospho-
mimetic T362E-PP5mutant hyper-dephosphorylates
substrates such as the co-chaperone Cdc37 and
glucocorticoid receptor in cells. Our proteomic
approach revealed that the tumor suppressor von
Hippel-Lindau protein (VHL) interacts with and ubiq-
uitinates K185/K199-PP5 for proteasomal degrada-
tion in a hypoxia- and prolyl-hydroxylation-indepen-
dent manner. Finally, VHL-deficient clear cell renal
cell carcinoma (ccRCC) cell lines and patient tumors
exhibit elevated PP5 levels. Downregulation of PP5
causes ccRCC cells to undergo apoptosis, suggest-
ing a prosurvival role for PP5 in kidney cancer.INTRODUCTION
The serine/threonine protein phosphatase 5 (PP5) belongs to the
phosphoprotein phosphatase (PPP) family. Unlike other phos-
phatases within this family, PP5 is encoded by a single gene,Cell Repor
This is an open access article under the CC BY-Nand its regulatory and catalytic domains are all contained within
the same polypeptide (Shi, 2009). Recently, a positive correlation
between PP5 expression levels and breast cancer metastasis
has been identified (Golden et al., 2008a), indicating that PP5
may act as an oncogene during carcinogenesis. Recent work
has also shown the importance of PP5 in colorectal cancer cell
growth (Wang et al., 2015).
PP5 generally has low basal activity, because the tetratrico-
peptide repeat (TPR) motif at its N terminus interacts with the
aJ helix in the C terminus. This prevents substrates from entering
the active site of PP5 (Cliff et al., 2006; Haslbeck et al., 2015a;
Kang et al., 2001; Ramsey and Chinkers, 2002; Yang et al.,
2005). Activation of PP5 depends on binding of its TPR domain
to the molecular chaperone heat shock protein 90 (Hsp90) and
client substrates. Other cellular factors such as polyunsaturated
fatty acids also activate PP5 (Chatterjee et al., 2010; Ramsey and
Chinkers, 2002; Yang et al., 2005).
The majority of PP5 substrates are in complex with Hsp90 and
include the glucocorticoid receptor (GR), tumor suppressor p53,
and the co-chaperone Cdc37 (Vaughan et al., 2008; Zuo et al.,
1998, 1999). PP5 also functions as a co-chaperone of Hsp90
(Haslbeck et al., 2015b; Vaughan et al., 2008; Wandinger et al.,
2006; Xu et al., 2012), and its dephosphorylation of Cdc37 in
complex with Hsp90 activates kinase clients. Hsp90 and its
co-chaperones are subject to post-translational modifications
(PTMs) (Mayer and Le Breton, 2015; Walton-Diaz et al., 2013;
Woodford et al., 2016a). However, it is unclear whether PP5 is
also subject to any PTMs and how this impacts its phosphatase
activity in cells. In this study, we found that CK1d phosphorylates
T362 in the catalytic domain of PP5, which is involved in its acti-
vation and hyperactivity, independent of Hsp90 binding. We also
found that the tumor suppressor vonHippel-Lindau protein (VHL)
targets K185/K199 for ubiquitination and proteasomal degrada-
tion of PP5 in a hypoxia-independent manner. Mutation andts 21, 1883–1895, November 14, 2017 ª 2017 The Author(s). 1883
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. CK1d Phosphorylates T362-PP5
(A) Empty vector (EV) or PP5-FLAG plasmids were transiently expressed and immunoprecipitated (IP) from HEK293 cells. Co-immunoprecipitation (Co-IP) of
endogenous CK1d was examined by immunoblotting. Empty vector was used as a control.
(B) PP5-FLAG and CK1d-cMyc were transiently co-expressed in HEK293 cells. PP5-FLAG was IP and Co-IP of CK1d-cMyc was assessed by immunoblotting.
Empty vector was used as a control.
(C) Recombinant PP5-His6 was used in an in vitro kinase assay. CK1d-GST phosphorylates only threonine residues on PP5-His6. Phosphorylation was examined
by immunoblotting with anti-phosphoserine or phosphothreonine antibodies. SE (short exposure) and LE (long exposure) of the radiographic film.
(D) Schematic representation of PP5 with highlighted CK1d consensus sequence E/DXXT.
(legend continued on next page)
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inactivation of VHL is associated with clear cell renal cell carci-
noma (ccRCC) (Cancer Genome Atlas Research Network,
2013). In the absence of VHL, PP5 was upregulated and hyper-
phosphorylated in ccRCC cells. Small interfering RNA (siRNA)-
mediated silencing of PP5 induced apoptosis in VHL-null
ccRCC, suggesting a prosurvival role for PP5 in these cells.
RESULTS
CK1d Phosphorylates T362 in the Catalytic Domain
of PP5
Previous work has shown that PP5 interacts with casein kinase 1
(CK1) (Partch et al., 2006). We used this information and showed
that in yeast, Hrr25, the homolog of mammalian serine/threonine
kinase casein kinase 1 d (CK1d), phosphorylates Ppt1 (yeast
PP5) on both serine and threonine residues (Figure S1A). This
was achieved by co-expressing C-terminally His6-tagged Ppt1
under its native promoter and C-terminally cMyc-tagged Hrr25
under the galactose-inducible promoter of GAL1 in yeast. Thre-
onine and serine phosphorylation of Ppt1-His6 was detectable
by immunoblotting using pan-anti-phosphothreonine-P6623
and anti-phosphoserine-P5754 (Sigma-Aldrich) antibodies (Fig-
ure S1A). Growing yeast cells in galactose (i.e., overexpressing
Hrr25-cMyc) led to hyperphosphorylation of Ppt1 on both threo-
nine and serine sites (Figure S1A). We next askedwhether similar
phenomena also occur with humanCK1d and human PP5. N-ter-
minal FLAG-tagged PP5 (PP5-FLAG) was transiently expressed
in HEK293 cells. Using anti-FLAGM2 affinity gel, PP5-FLAGwas
immunoprecipitated, and co-immunoprecipitation of CK1d was
observed by immunoblotting (Figure 1A). A similar experiment
was also conducted by transiently co-transfecting HEK293 cells
with PP5-FLAG and N-terminally cMyc-tagged CK1d. Immuno-
precipitation of PP5-FLAG led to co-immunoprecipitation of
CK1d-cMyc (Figure 1B). These data show that CK1d interacts
with PP5.
Our previous work has shown that PP5-mediated dephos-
phorylation of the co-chaperone Cdc37 is essential for activation
of the kinase clients of Hsp90 (Vaughan et al., 2008). We first es-
tablished whether CK1d is an Hsp90 client by treating HEK293
cells with 1 mM of the Hsp90 inhibitor ganetespib (GB) over
time. This did not impact the stability of CK1d (Figure S1B);
therefore, it is unlikely that CK1d is a client of Hsp90. We next
examined whether CK1d directly phosphorylates PP5 in an
in vitro kinase assay. Bacterially expressed and purified PP5-
His6 was bound to Ni-NTA agarose and then incubated with
active CK1d-glutathione S-transferase (GST). Using immuno-
blotting and anti-phosphothreonine P6623 (Sigma-Aldrich) anti-
body, it was possible to detect threonine phosphorylation of PP5(E) Potential CK1d-targeted threonine sites on PP5 are highlighted on the cartoo
software (PDB: 1WAO) and colored in red as in (D).
(F) PP5-threonine residues within the CK1d consensus sequence were mutated
Threonine phosphorylation was detected by immunoblotting with anti-phosphoth
cMyc with the phospho-PP5-FLAG mutants in HEK293 cells. PP5-FLAG and
immunoblotting with anti-phosphothreonine antibody. Short exposure (SE) and l
(G) Recombinant PP5-His6 and T362A-PP5-His6 were used as substrates of CK
noblotting with anti-phosphoserine or phosphothreonine antibodies.
See also Figure S1.(Figure 1C). Unlike in yeast, CK1d does not phosphorylate any
serine sites on PP5 (Figure 1C). There are seven mammalian
CK1 isoforms, but CK1d and CK1ε display the highest homology
(Schittek and Sinnberg, 2014). We repeated our in vitro kinase
assay with PP5-His6 and CK1ε-GST. Surprisingly, CK1ε did not
phosphorylate PP5 on threonine or serine sites (Figure S1C).
Generally, the CK1 consensus phosphorylation site is S/Tp-X-
X-S/T, where S/Tp refers to phospho-serine or phospho-threo-
nine priming sites, X refers to any amino acid, and the underlined
residues refer to the target site (Flotow et al., 1990). We did not
identify any possible threonine phosphorylation site using this
consensus motif in PP5. CK1 also phosphorylates a related un-
primed site, D/E-X-X-S/T, where the underlined residues refer to
the phosphorylated amino acid (Flotow et al., 1990). We identi-
fied five threonine residues within this CK1 consensus site (Fig-
ure 1D): T33, T121, T171, T238, and T362. With the exception
of T238, all the identified threonine sites are located on the sur-
face of PP5 (Figure 1E). These sites were individually mutated
to non-phosphorylatable alanine in the PP5-FLAG construct
and transiently co-expressed with or without CK1d-cMyc in
HEK293 cells. PP5-FLAG was then immunoprecipitated with
anti-FLAG M2 affinity gel, and threonine phosphorylation was
detected by immunoblotting using anti-phosphothreonine-
P6623 (Sigma-Aldrich) antibody. Overexpression of CK1d-
cMyc increased threonine phosphorylation of wild-type PP5-
FLAG and all non-phosphorylatable threonine mutants except
T362A-PP5-FLAG (Figures 1F and S1D). The threonine phos-
phorylation of this mutant was significantly lower, even with
overexpression of CK1d-cMyc (Figures 1F and S1D), suggesting
that T362 is phosphorylated by CK1d. We obtained further
evidence by carrying out an in vitro kinase assay with bacterially
expressed and purified wild-type PP5-His6 and the non-phos-
phorylatable mutant T362A-PP5-His6. We were unable to detect
threonine phosphorylation of this mutant by immunoblotting
(Figure 1G), therefore confirming that CK1d targets and phos-
phorylates only T362 in PP5.
T362 Phosphorylation Activates and Increases PP5
Activity Independent of Hsp90
To determine the impact of T362 phosphorylation on the activa-
tion and activity of PP5, we initially tested the ability of T362-PP5
phosphomutants to dephosphorylate para-nitrophenyl phos-
phate (pNPP), a small molecule commonly used for assaying
nonspecific phosphatase activity (Oberoi et al., 2016). Our data
showed that the bacterially expressed and purified wild-type-
PP5-His6 had basal phosphatase activity, and the addition of
Hsp90a stimulated this activity (Figures S2A and S2B). Phospho-
mimetic T362E-PP5-His6 or CK1d mediated phosphorylation ofn representation of the PP5 protein, which was modeled with UCSF Chimera
individually to alanine (A), transiently expressed, and IP from HEK293 cells.
reonine antibody. This experiment was repeated with co-transfection of CK1d-
its mutants were isolated and threonine phosphorylation was assessed by
ong exposure (LE) of the radiographic film.
1d-GST in an in vitro kinase assay. Phosphorylation was assessed by immu-
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Figure 2. CK1d-Mediated Phosphorylation
of PP5 Activates and Increases the Rate of
Phosphatase Activity
(A) Dephosphorylation of phospho-S13-Cdc37
with a recombinant wild-type PP5-His6 and
phosphomimetic T362E-PP5-His6 in the presence
of Hsp90a. The rate of Cdc37 dephosphorylation
was assessed by immunoblotting with a phospho-
specific S13-Cdc37 antibody over time (minutes).
(B) Recombinant wild-type PP5-His6 was phos-
phorylated by CK1d in vitro and then used
in the dephosphorylation of phospho-S13-Cdc37
in vitro. The assay was performed in the presence
of Hsp90a. PP5 activity was assessed with
immunoblotting using a phospho-specific S13-
Cdc37 antibody over time (minutes).
(C) Dephosphorylation of phospho-S13-Cdc37
with recombinant wild-type PP5-His6 and phos-
phomimetic T362E-PP5-His6 was performed in
the absence of Hsp90a. Activity was assessed
with immunoblotting using a phospho-specific
S13-Cdc37 antibody over time (minutes).
(D) Recombinant wild-type PP5-His6 was phos-
phorylated by CK1d in vitro and then used in the
dephosphorylation of phospho-S13-Cdc37 in vitro
without Hsp90a. PP5 activity was assessed with
immunoblotting using a phospho-specific S13-
Cdc37 antibody over time (minutes).
(E) Recombinant PP5-His6 was used in an
in vitro kinase assay with CK1d-GST. PP5-His6
was immunoprecipitated (IP), and threonine
phosphorylation of PP5 and co-immunoprecipita-
tion (Co-IP) of CK1d-GST were examined by
immunoblotting with anti-phosphothreonine and
anti-GST antibodies.
(F) Recombinant wild-type PP5-His6 was phos-
phorylated by CK1d in vitro in the presence (+) or
absence () of ATP. PP5-His6 proteins were then
used in the dephosphorylation of phospho-S13-
Cdc37 in vitro without Hsp90a. PP5 activity was
assessed with immunoblotting using a phospho-
specific S13-Cdc37 antibody over time (minutes).
(G) PP5-FLAG and T362-PP5 phosphomutants
(T362A and T362E) were transiently transfected
in HEK293 cells. Cdc37, phospho-S13-Cdc37,
GR, and phospho-S211-GR protein levels were
examined by immunoblotting. Empty vector (EV) was used as a control, and GAPDH was used as a loading control.
(H) Wild-type PP5-FLAG, non-phosphorylating T362A-PP5-FLAG, and phosphomimetic T362E-PP5-FLAGwere transiently expressed and IP fromHEK293 cells.
Co-IP of GR, Cdc37, and Hsp90 was examined by immunoblotting.
See also Figure S2.T362-PP5-His6-stimulated PP5 activity in the absence of
Hsp90a (Figures S2A and S2B). We repeated the same experi-
ments but instead used non-phosphorylating T362A-PP5-His6.
This mutant had basal phosphatase activity similar to that of
wild-type-PP5-His6, suggesting that the mutation did not struc-
turally affect PP5 activity. However, the addition of Hsp90a or
CK1d (in an attempt to phosphorylate T362A-PP5-His6 in vitro)
did not stimulate phosphatase activity (Figures S2A and S2B).
We next used an in vitro dephosphorylation assay of phospho-
S13-Cdc37, which is a bona fide substrate of PP5 (Vaughan
et al., 2008). We first showed that the addition of Hsp90a to
wild-type PP5 leads to complete dephosphorylation of phos-
pho-S13-Cdc37 after 30 min (Figures 2A and 2B). However,1886 Cell Reports 21, 1883–1895, November 14, 2017the addition of Hsp90a to phosphomimetic T362E-PP5-His6
(Figure 2A) or phospho-T362-PP5-His6 (Figure 2B) led to
dephosphorylation of Cdc37 after only 10 min. To determine
whether activation of phospho-T362-PP5 is independent of
Hsp90, we repeated the above experiment in the absence
of Hsp90a. Our data revealed that wild-type PP5 is unable
to dephosphorylate phospho-S13-Cdc37 in the absence of
Hsp90a (Figures 2C and 2D). However, phosphomimetic
T362E-PP5-His6 (Figure 2C) or CK1d mediated phosphorylation
of T362-PP5 dephosphorylated (Figure 2D) phospho-S13-
Cdc37 in vitro, even in the absence of Hsp90.
To ascertain whether CK1d’s interaction with PP5 caused an
increase in its phosphatase activity, CK1d was incubated with
PP5-His6 in the presence and absence of ATP. CK1d has the
ability to interact with PP5-His6 independent of ATP (Figure 2E).
However, only CK1d’s incubation with PP5-His6 in the presence
of ATP (hence phosphorylation of PP5) is capable of activating
PP5. This leads to dephosphorylation of PP5 substrate,
(i.e., phospho-S13-Cdc37) (Figure 2F). Taken together, these
in vitro data suggest that CK1d-mediated phosphorylation of
T362-PP5 causes activation and hyperactivity of PP5 phospha-
tase independent of binding to Hsp90.
To obtain further evidence for this observation, we overex-
pressed wild-type PP5-FLAG and the phosphomutants T362A
and T362E in HEK293 cells. The dephosphorylation of PP5
substrates, phospho-S13-Cdc37 and phospho-S211-GR, was
examined by immunoblotting. Overexpression of wild-type
PP5-FLAG led to dephosphorylation of phospho-S13-Cdc37
and phospho-S211-GR (Figure 2G). This effect was enhanced
by overexpression of phosphomimetic T362E-PP5-FLAG and
unaffected (similar to the empty vector control) by T362A-PP5-
FLAG, which is consistent with our in vitro data (Figure 2G).
Finally, we confirmed that the interactions between the phos-
pho-T362 mutants and Hsp90, Cdc37, and GR were not
affected, and therefore, our observation is not due to a lack of
interaction between PP5mutants and the substrates (Figure 2H).
Our in vitro and in vivo data here show that phosphorylation of
T362-PP5 is involved in both the activation and hyperactivity of
PP5. Furthermore, based on our in vitro results, CK1d-mediated
phosphorylation and activation of PP5 does not depend on
binding to Hsp90.
VHL E3 Ligase Targets PP5 Independent of Hypoxia
To determine which binding partners of PP5 are involved in
its regulation, we immunoprecipitated endogenous PP5 from
HEK293 cells and identified its intracellular binding proteins by
mass spectrometry (MS) analysis (see Experimental Proced-
ures). Our interactome data identified VHL as a binding partner
of PP5 (Table S1). VHL forms a multi-protein complex, VCB-
Cul2 (VHL-elongin C-elongin B-cullin 2) and Rbx1, that acts as
a ubiquitin ligase (E3) (Gossage et al., 2015; Kamura et al.,
1999; Stebbins et al., 1999) and directs proteasome-dependent
degradation of targeted proteins such as hypoxia-inducible fac-
tors (HIF1a or HIF2a) (Kamura et al., 2000). VHL is expressed as
two known isoforms: VHL30, with an apparent molecular weight
of 24–30 kDa (VHL30), and VHL19, which is 19 kDa in size
(Iliopoulos et al., 1995). Both isoforms appear to retain tumor-
suppressor activity; however, VHL30 is the commonly examined
isoform. Here, we confirmed our interactome data by immuno-
precipitating endogenous PP5 from HEK293 cells and detecting
VHL30 (Figure 3A). The reciprocal immunoprecipitation of the
endogenous VHL30 yielded PP5 (Figure 3B). Since VHL is the
substrate recognition subunit of an E3 ubiquitin ligase, we over-
expressed VHL30 in the VHL-deficient ccRCC cell line 786-O and
observed downregulation of endogenous PP5 by immunoblot-
ting (Figure 3C). We next transiently transfected and expressed
PP5-FLAG in the 786-O cell line. Using immunoprecipitation
and immunoblotting, we were unable to detect PP5 ubiquitina-
tion in these cells (Figure 3D), even when treated with 50 nM of
the proteasome inhibitor bortezomib (BZ) for 2 hr (Figure 3D).
However, transient co-expression of PP5-FLAG and VHL30-His6 in 786-O cells for 16 hr and subsequent treatment with
50 nM BZ for 2 hr led to detection of distinct ubiquitination
bands, suggesting multi-monoubiquitination of PP5-FLAG (Fig-
ure 3D). It is noteworthy that the anti-ubiquitin antibody used in
these experiments (P4D1) recognizes both mono- and poly-
ubiquitination. Taken together, these data suggest that VHL E3
ligase ubiquitinates and degrades PP5 in the proteasome.
Canonically, VHL substrates are recognized when hydroxyl-
ated by prolyl-hydroxylases (PHDs) at specific proline sites
(Ivan et al., 2001; Jaakkola et al., 2001). To determine whether
hydroxylation was essential for VHL-mediated ubiquitination
of PP5, we first overexpressed three EGLN genes (EGLN1,
EGLN2, and EGLN3) encoding for three isoforms of PHDs in
HEK293 cells. Overexpression of these genes did not affect
the endogenous PP5 protein levels but, as expected, markedly
reduced HIF1a levels (Figure 3E). Treatment of HEK293 cells
with the PHD inhibitor dimethyloxaloylglycine (DMOG) or the
hypoxia mimetic deferoxamine (DFX) or CoCl2 similarly did not
affect PP5 protein levels (Figure S3A). As expected, these condi-
tions all led to stabilization of HIF1a (Figure S3A). We obtained a
similar result when we treated the Caki-1 ccRCC cell line (con-
taining the wild-type VHL gene) with DMOG, DFX, or CoCl2 (Fig-
ure S3B). Finally, we examined PP5 protein levels in Caki-1 cells
cultured in normoxia and hypoxia (1%O2, 5%CO2, and 94%N2).
While HIF1a levels increased under hypoxia, PP5 levels were un-
changed and similar to normoxia (Figure 3F). Finally, previous
work has indicated that transcription of PP5 can be mediated
by HIF1 (Zhou et al., 2004). We examined this possibility by using
siRNA to silence HIF1a or HIF2a in HEK293 cells. Our results
showed that neither HIF1a nor HIF2a is involved in the regulation
of PP5 (Figure 3G). We conducted a similar experiment in 786-O
ccRCC cells and silenced only HIF2a (HIF1a is downregulated in
these cells). Our data also showed that HIF2a is not involved in
PP5 expression in VHL-null 786-O cells (Figure S3C). These
data indicate that VHL ubiquitinates PP5 independent of prolyl-
hydroxylation and hypoxia.
VHL Ubiquitinates K185/K199-PP5
Based on the data available on PhosphoSitePlus (https://www.
phosphosite.org), an online systems biology resource providing
comprehensive information on PTMs of human proteins, we
identified five ubiquitinated lysine sites (K32, K40, K185, K199,
and K320) on PP5 (Figure 4A). All of these sites are located
on the surface of the PP5 protein (Figure 4B). We individually
mutated these lysine sites to a non-ubiquitinating arginine resi-
due and transiently expressed them in HEK293 cells (Figure 4C).
Ubiquitination of wild-type PP5 was detectable by immunopre-
cipitation and immunoblotting techniques (Figures 4C and
S4A). However, ubiquitination of PP5 was significantly reduced
in the K185R and K199R mutants (Figure 4C). Our data also
showed that K185R and K199R-PP5-FLAG mutants were
slightly more stable than the wild-type PP5-FLAG expressed
in HEK293 cells (Figure S4B), whereas these mutants were
expressed at the same levels as the wild-type PP5-FLAG in the
VHL-null 786-O cells (Figure S4C).
We next created a K185R/K199R-PP5-FLAG double mutant
and transiently expressed it in HEK293 cells. Ubiquitination of
this mutant was undetectable by immunoprecipitation andCell Reports 21, 1883–1895, November 14, 2017 1887
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Figure 3. VHL E3 Ligase Ubiquitinates PP5
Independent of Hypoxia
(A) Endogenous PP5 was immunoprecipitated (IP)
from HEK293 cells, and co-immunoprecipita-
tion (Co-IP) of VHL30 was assessed by immuno-
blotting.
(B) Endogenous VHL30 was IP from HEK293
cells, and Co-IP of PP5 was examined by immu-
noblotting.
(C) VHL30-FLAG or empty vector (EV) was tran-
siently overexpressed in 786-O cells and endoge-
nous PP5 protein levels were assessed by immu-
noblotting. GAPDH was used as a loading control.
(D) 786-O cells transiently expressing PP5-FLAG
were treated with or without 50 nM of the protea-
some inhibitor bortezomib (BZ) for 2 hr. PP5-FLAG
was also co-expressed with VHL30-His6 with
additional treatment of 50 nM BZ for 2 hr. PP5-
FLAG was IP, and its ubiquitination was assessed
by immunoblotting.
(E) Egln1-HA, Egln2-HA, Egln3-HA, and empty
vector (EV) pcDNA3.1 were transiently overex-
pressed in HEK293 cells. The expression of Egln1,
2, and 3, as well as PP5 and HIF1a, was assessed
by immunoblotting with anti-HA, anti-PP5, and
anti-HIF1a antibodies. GAPDH was used as a
loading control.
(F) Caki-1 cells cultured in normoxia and hypoxia
(1%O2, 5%CO2, 94%N2). PP5 and HIF1a protein
levels were examined by immunoblotting using
anti-PP5 and anti-HIF1a antibodies. GAPDH was
used a loading control.
(G) HIF1a or HIF2a were silenced by small inter-
fering RNA (siRNA) in HEK293 cells. HIF1a, HIF2a
and PP5 protein levels were examined by immu-
noblotting using anti-HIF1a, anti-HIF2a and anti-
PP5 antibodies. GAPDH was used as a loading
control.
See also Figure S3.immunoblotting experiments (Figures 4D and S4D). To deter-
mine whether VHL is responsible for ubiquitination of these sites,
we used an in vitro ubiquitination assay kit (Millipore) with the
VCB-Cul2 complex (Figure S4E). As mentioned earlier, VHL is
part of a multi-protein complex, VCB-Cul2 and Rbx1, acting as
a ubiquitin ligase (E3) and directing proteasome-dependent
degradation of targeted proteins. Next, bacterially expressed
and purified wild-type PP5-His6 and K185R/K199R-PP5-His6
double mutant were used in our in vitro ubiquitination assay.
Our data show that recombinant wild-type PP5-His6, but not
the K185R/K199R-PP5-His6 mutant, was subject to ubiquitina-
tion. Based on the immunoblots and the appearance of the
bands, our data suggest that PP5 is subject to multi-monoubi-
quitination (Figure 4E), therefore suggesting that VHL targets
K185/K199-PP5 for ubiquitination. To gain further evidence
of VHL-mediated ubiquitination of K185/K199-PP5 in cells,
we transiently co-expressed wild-type PP5-FLAG or K185R/1888 Cell Reports 21, 1883–1895, November 14, 2017K199R-PP5-FLAG with VHL30-His6 for
16 hr in VHL-null 786-O cells and then
treated the cells with 50 nM BZ for an
additional 2 hr. We were able to detectthe ubiquitination of wild-type PP5, but not the K185R/K199R-
PP5 double mutant (Figure 4F). The K185R-, K199R-PP5
single or double mutants interacted with the same affinity
as wild-type PP5 to VHL30 (Figure 4G). Therefore, the reduced
ubiquitination of these mutants is not due to their inability to
bind to VHL30.
Taken together, our data show that VHL E3 ligase ubiquiti-
nates K185 and K199 residues in PP5.
PP5 Downregulation Causes Apoptosis in VHL-Null
ccRCC Cells
To gain further insight into the significance of PP5 stability and
hyperactivity in ccRCC, we first examined PP5 protein levels
in tumors and adjacent normal tissues from nine patients
with ccRCC. Within 10 min of removal of tumors by radical or
partial nephrectomy, tumors and adjacent normal tissues were
dissected into 10-mm3 pieces and stained with H&E (Figure 5A),
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Figure 4. VHL-Mediated Ubiquitination and
ProteasomalDegradationofK185/K199-PP5
(A) Schematic representation of PP5 highlighting
the lysine residues possibly subject to VHL-medi-
ated ubiquitination.
(B) Potential ubiquitinating lysine residues are
highlighted in the cartoon representation of the
PP5 protein, which was modeled with UCSF
Chimera software (PDB: 1WAO) and colored in red
as in Figure 1D.
(C) Wild-type PP5-FLAG and its potentially
non-ubiquitinating lysine mutants were transiently
expressed and immunoprecipitated (IP) from
HEK293 cells. Ubiquitination of PP5 was examined
by immunoblotting. Empty vector (EV) was used as
a control.
(D) Wild-type PP5-FLAG and its non-ubiquitinating
K185/K199R mutant were transiently expressed
and IP from HEK293 cells. Ubiquitination of PP5
was examined by immunoblotting anti-ubiquitin
antibody. Empty vector (EV) was used as a control.
(E) Recombinant PP5-His6 and K185/K199R dou-
ble mutant were used in an in vitro ubiquitination
assay with VCB-Cul2 (VHL30-elongin C-elongin
B-cullin 2) and Rbx1, which acts as an ubiquitin-
ligase (E3). Ubiquitination of PP5 was assessed
with immunoblotting.
(F) PP5-FLAG or K185/K199R-PP5-FLAG double
mutant was co-transfected with VHL30-His6 in
786-O cells and treated 16 hr later with 50 nM
BZ for 2 hr. PP5-FLAG or K185/K199R-PP5-
FLAG was IP, and ubiquitination was assessed by
immunoblotting.
(G) PP5-FLAG, K185-PP5-FLAG, K199R-PP5-
FLAG, K185/K199R-PP5-FLAG, and empty vector
(EV) were individually and transiently expressed
in HEK293 cells. They were IP, and their in-
teractions with VHL30 were assessed in the Co-IP
by immunoblotting.
See also Figure S4.and protein was extracted (Figure 5B). Our data showed
that VHL30 is absent in ccRCC tumors. Conversely PP5 and
CK1d were both upregulated in tumors compared with adjacent
normal tissue (Figure 5B).
We confirmed this finding using established VHL-deficient
(786-O and A-498) and VHL-containing (Caki-1) ccRCC cell lines.
Our data showed that PP5 was upregulated in 786-O and A-498
cells compared to Caki-1 cells (Figure 5C). CK1d levels displayed
a similar expression pattern, while CK1ε levels were unchanged
between VHL-deficient and VHL-containing ccRCC cell lines
(Figures 5C and S5A). This pattern was consistent with dephos-
phorylation of the PP5 substrates Cdc37 and GR, which were
both more dephosphorylated in 786-O and A-498 cells than in
VHL-containing Caki-1 cells (Figure 5C). We next used siRNA to
silence PP5 in 786-O and Caki-1 cells and observed inductionCell Reportof the pro-apoptotic markers cleaved
caspase-3 and cleaved-poly-ADP-ribose
polymerase (PARP) only in VHL-null
786-O cells (Figure 5D). We also found
that silencing of PP5 in 786-O cells didnot affect CK1d protein levels (Figure S5B). Furthermore, siRNA
silencing of PP5 in A-498 cells (VHL-null cell line) also led to
induction of the apoptotic markers cleaved caspase-3 and
cleaved PARP (Figure 5E).
To evaluate the threonine phosphorylation status of PP5
in VHL-null cells, we immunoprecipitated endogenous PP5
from 786-O and Caki-1 cells and found that PP5 from VHL-null
786-O cells was hyperphosphorylated on threonine residues
(Figure 5F). Because IC261 is a potent specific inhibitor of
CK1d/ε, we next examined whether pharmacologic inhibition
of CK1d reduces threonine phosphorylation of PP5. In 786-O
cells treated or untreated with 2 mM IC261 for 16 hr, PP5 was
immunoprecipitated and as expected, IC261 treatment led to a
marked reduction of PP5 threonine phosphorylation but not
serine phosphorylation (Figure 5G). Taken together, our datas 21, 1883–1895, November 14, 2017 1889
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Figure 5. Downregulation of PP5 Induces Apoptosis in VHL-Deficient ccRCC Cells
(A) Clear cell renal cell carcinoma (ccRCC) tumors (T) and adjacent normal tissue (N) were stained with H&E. Scale bar represents 200 mm.
(B) Protein was extracted from tumors and adjacent normal tissue, and expression of PP5, CK1d, VHL30, and Hsp90 was examined by immunoblotting. Hsp90
was used as a loading control.
(legend continued on next page)
1890 Cell Reports 21, 1883–1895, November 14, 2017
show that PP5 is upregulated and phosphorylated by CK1d in
VHL-null ccRCC cells. Downregulation of PP5 in VHL-null cells
causes apoptosis.
PP5 Upregulation Provides a Prosurvival Mechanism in
VHL-Null ccRCC Cells
We next examined whether pharmacologic inhibition of CK1d
causes apoptosis in VHL-null cells (A498 and 786-O). We used
Caki-1 cells as a control, because this ccRCC cell line has the
VHL gene. These cell lines were treated with different amounts
of IC261, which is a potent specific inhibitor of CK1d/ε.
Increasing amounts of IC261 correlated with increased induction
of the pro-apoptotic markers cleaved caspase-3 and cleaved
PARP only in A498 and 786-O (VHL-null) cells (Figure 6A).
Another hallmark of apoptosis is the loss of cell membrane integ-
rity, which can be monitored by Annexin V/propidium iodide
(AV/PI) staining. We treated A498, 786-O, and Caki-1 cells with
0.5 mM and 2.0 mM IC261 for 16 hr prior to analysis of apoptosis
by AV/PI staining. Treatment of A498 and 786-O cells with 2.0 mM
IC261 caused cells to progress through the AV+/PI apoptotic
quadrant (Figures 6B and S6A). However, this effect was not
observed in Caki-1 cells after the same treatment with IC261
(Figures 6B and S6A). We next examined the effects of IC261
on proliferation of ccRCC cell lines. A498, 786-O, and Caki-1
cells were treated with different amounts of CK1d inhibitor
(IC261). After 72 hr, proliferation was measured by a 3-(4,
5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT)
assay. Our data revealed that 2.0 mM IC261 significantly inhibited
the proliferation of A498 and 786-O cells compared to Caki-1
cells (Figure 6C). A hallmark of tumorigenic cells is anchorage-
independent growth, which is measurable by soft agar assay.
Treatment with 2.0 mM IC261 significantly reduced the
anchorage-independent growth of A498 and 786-O cells
compared to Caki-1 cells (Figures 6D and S6B).
Although treatment of VHL-null cells with IC261 caused
apoptosis, it is unclear whether this effect was due to lack of
PP5 phosphorylation and activity. We addressed this question
by transiently expressing wild-type PP5-FLAG and its phos-
pho-PP5mutants T362A and T362E in 786-O cells. Treating cells
expressing empty vector (EV) or non-phosphorylatable T362A-
PP5-FLAG mutant with 2.0 mM IC261 led to induction of the
pro-apoptotic markers cleaved caspase-3 and cleaved PARP.
This effect was significantly reduced upon expression of wild-
type PP5-FLAG and completely abrogated with the phospho-
mimetic T362E-PP5-FLAG mutant (Figure 6E). We further
confirmed these data using an MTT assay. Our data showed(C) PP5, Cdc37, and phosphorylated S13-Cdc37, GR, phosphorylated S211-G
deficient), and Caki-1 (VHL containing) were assessed by immunoblotting. GAPD
(D) PP5 was silenced by siRNA in 786-O and Caki-1 cells. siCtrl represents the
noblotting using anti-cleaved caspase-3 and cleaved PARP antibodies. GAPDH
(E) Targeted siRNA was used to silence PP5 in A498 cells. siCtrl represents the
noblotting using anti-cleaved caspase-3 and cleaved PARP antibodies. PP5 pr
control.
(F) PP5 was immunoprecipitated (IP) from ccRCC cell line (Caki-1 and 786-O) ly
phosphorylation of PP5 was assessed by immunoblotting with anti-phosphothre
(G) PP5was isolated from the lysates of 786-O cells treatedwith 2 mM IC261 for 16
was examined by immunoblotting using anti-phosphothreonine antibody. Anti-p
See also Figure S5.that treatment of 786-O cells transiently expressing EV or non-
phosphorylatable T362A-PP5-FLAG mutant with 2.0 mM IC261
caused a marked reduction in cell proliferation, whereas this
effect was not observed in 786-O cells expressing wild-type
PP5-FLAG and phosphomutant T362E-PP5 treated with
2.0 mM IC261 (Figures 6F and S6C).
Taken together, our findings show that pharmacologic inhibi-
tion of CK1d causes apoptosis in ccRCC cells, and this effect
is mediated by a lack of threonine phosphorylation of PP5 and
reduced phosphatase activity.
DISCUSSION
PP5 plays a key role in the regulation of both hormone- and
stress-induced signaling networks that allow cells to respond
appropriately to genomic stress (Golden et al., 2008b). Struc-
tural work and in-vitro-based assays have shown that PP5 ac-
tivity is promoted by a number of cellular factors, including the
molecular chaperone Hsp90 and fatty acids, both of which
release autoinhibition by interacting with the TPR domain of
PP5 (Ramsey and Chinkers, 2002; Yang et al., 2005). In this
study, we elucidated an alternative mechanism for activation
and regulation of PP5 both in vitro and in vivo. Our data showed
that the serine/threonine kinase CK1d interacts with and phos-
phorylates T362 on PP5. This in turn activates PP5 independent
of binding to Hsp90. We have also shown that CK1d is not
a client of Hsp90, because pharmacologic inhibition of Hsp90
did not affect the stability of CK1d. Additionally, binding of
CK1d to PP5, without phosphorylation, is insufficient to activate
PP5. Our cell-based assays have demonstrated that expression
of non-phosphorylating T362A-PP5 did not dephosphorylate
PP5 substrates such as GR and Cdc37, whereas overexpres-
sion of phosphomimetic T362E-PP5 had the opposite effect
on those two substrates. Our findings clearly demonstrate
that although phosphorylation of T362-PP5 does not affect
the binding of PP5 to its substrates or even Hsp90, the phos-
phatase activity of PP5 is influenced by T362 phosphorylation
(Figure 7).
What is the mechanism of phosphorylation-mediated PP5
activation? Threonine-362 is close to one of the six metal-coor-
dinating sites, H352, but it is remote from the catalytic site. T362
is also at the center of an acidic patch located between D365,
D364 and E416, E417. The latter residues are linked to the active
site R400. Therefore, it is conceivable that phosphorylation or
phosphomimetic mutation of T362 could either destabilize the
domain as a whole or cause some local unfolding, possiblyR, CK1d, and VHL30 proteins from the ccRCC cell lines 786-O, A-498 (VHL
H was used as a loading control.
non-targeting siRNA control. Induction of apoptotic markers shown by immu-
was used as a loading control.
non-targeting siRNA control. Induction of apoptotic markers shown by immu-
otein levels were also examined by immunoblotting. GAPDH was used as a
sates using anti-PP5 antibody or immunoglobulin G (IgG) (control). Threonine
onine antibody. GAPDH was used as a loading control.
hr using anti-PP5 or IgG (control) antibodies. Threonine phosphorylation of PP5
hosphoserine antibody was used as a control.
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Figure 6. CK1d Inhibition Induces Apoptosis and Reduced Proliferation in VHL-Null ccRCC Cells
(A) The ccRCC cell lines A498, 786-O, and Caki-1 were treated with the indicated amounts of the CK1d inhibitor IC261 for 16 hr. Induction of apoptotic markers
was assessed by immunoblotting using anti-cleaved caspase-3 and cleaved PARP antibodies. GAPDH was used as a loading control.
(B) AV/PI graphs of Caki-1, A498, and 786-O cells not treated (0 mM) or treated with 2 mM IC261 for 16 hr. The top left quadrants represent dead cells stained only
with PI. The bottom right quadrants represent apoptotic cells stained with AV only. The top right quadrants represent cells stained with both PI and AV (secondary
necrosis and late apoptosis). The percentage of each stained cell population is indicated. Dot plots shown are representative of one of three independent
experiments.
(legend continued on next page)
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CK1d-mediated phosphorylation of T362 in the cat-
alytic domain of PP5 activates and enhances its
phosphatase activity, therefore dephosphorylating
its substrates, such as the co-chaperone Cdc37 and
the steroid hormone receptor GR. VCB-Cul2 (VHL-
elongin C-elongin B-cullin 2) and Rbx1 (E3 ubiquitin
ligase) target and ubiquitinate K185 and K199 on
PP5. This leads to proteasomal degradation of PP5.allosterically ‘‘opening’’ the active site, therefore increasing the
rate of phosphatase activity.
Our proteomic data also identified an interaction between the
tumor suppressor VHL and PP5. VHL is an E3 ligase that canon-
ically recognizes its substrates as part of an oxygen-dependent
PHD reaction, with HIFa being its most-studied substrate
(Clifford et al., 2001; Kondo et al., 2002; Maxwell et al., 1999).
Our data revealed that PP5 is a hypoxia-independent target
for VHL ubiquitination. We also showed that VHL ubiquitinates
K185/K199-PP5 to target this phosphatase for proteasome-
mediated degradation (Figure 7). Our finding of a hypoxia-
independent function of VHL is not unusual; recent work has
shown that VHL also directly multi-monoubiquitinates Aurora
kinase A (AURKA) independent of oxygen or PHD activity (Hasa-
nov et al., 2017).(C) MTT assay of A498, 786-O, and Caki-1 cells treated with the indicated amounts of IC261. Errors bars
(****p < 0.0001).
(D) Anchorage-independent growth of A498, 786-O, and Caki-1 cells treated with indicated amounts of IC2
errors bars represent the SD of three independent experiments (***p < 0.0005).
(E) Wild-type PP5-FLAG, non-phosphorylating T362A-PP5-FLAG, and phosphomimetic T362E-PP5-FLA
were then either not treated (IC261) or treated (+IC261) with 2 mM IC261 for 16 hr, and induction of apopto
anti-cleaved caspase-3 and cleaved PARP antibodies. GAPDH was used as a loading control.
(F) MTT assay of 786-O cells transiently expressing wild-type PP5-FLAG, T362A-PP5-FLAG, and T362E-PP
of IC261. Errors bars represent the SD of three independent experiments (**p < 0.005; ***p < 0.0005).
See also Figure S6.
Cell ReporMutation and inactivation of VHL is
associated with the most common
type of kidney cancer, ccRCC (Cancer
Genome Atlas Research Network, 2013;
Gossage et al., 2015). We further demon-
strated that inactivation of VHL in tumors
or established cell lines leads to increased
PP5 protein levels. This appeared to be in-
dependent of HIF1a or HIF2a. Our findings
also provided a prosurvival role for PP5 in
VHL-null kidney cancer cells. Downregula-
tion of PP5 by siRNA activated apoptosis
in ccRCC cells. This effect was apparent
only in VHL-null ccRCC cells. We also
showed that pharmacologic inhibition of
CK1d by IC261 leads to apoptosis and
decreased proliferation of ccRCC cells.
This effect was completely abrogated
by overexpressing the phosphomimetic
T362E-PP5 mutant in IC261-treated VHL-
null ccRCC cells. Our findings thereforestrongly suggest that the apoptotic effect of CK1d inhibition is
mediated by a lack of phosphorylation and thus inactivation of
PP5 in ccRCC cells. It is worth noting that IC261 is also a potent
inhibitor of CK1ε; however, CK1ε does not phosphorylate PP5.
Although the apoptotic effect of IC261 may be the result of CK1ε
inhibition, this possibility is highly unlikely, because treatment of
786-O cells overexpressing phosphomimetic T362E-PP5 with
IC261 did not induce apoptosis.
Based on previous studies, there is circumstantial evidence
suggesting that aberrant expression of PP5may aid tumor devel-
opment and progression (Golden et al., 2008a; Wang et al.,
2015). Our study here also suggests that upregulation of PP5 is
essential for ccRCC cell survival, but how is this achieved by
PP5? Our previous work has shown that PP5-mediated dephos-
phorylation of the co-chaperone Cdc37 is essential for activationrepresent the SD of three independent experiments
61 in soft agar. Colony number was quantified. The
G were transiently expressed in 786-O cells. Cells
tic markers was assessed by immunoblotting using
5-FLAG and then treated with the indicated amounts
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of the kinase client proteins of Hsp90 (Vaughan et al., 2008).
Several of these clients, including vascular endothelial growth
factor (VEGF) and platelet-derived growth factor (PDGF) recep-
tors, as well as the mammalian target of rapamycin (mTOR),
are important in ccRCC (Gossage et al., 2015; Linehan, 2012)
and therefore potentially rely on the co-chaperone activity of
PP5. Downregulation of PP5 in these cells appears to be detri-
mental for ccRCC cell survival, perhaps because of compro-
mised function of these kinases. PP5 has been shown to be a
negative regulator of the ASK1/MKK4/JNK signaling that pro-
motes apoptosis (Zhou et al., 2004), and its overexpression, un-
der hypoxia, in breast cancer has been shown to turn off this
apoptotic signaling pathway. In contrast to a previous study
(Zhou et al., 2004), we were unable to showHIF1 or HIF2 involve-
ment in the regulation of PP5.
Further investigation is warranted to identify the exact
signaling pathways dependent on PP5 function in VHL-null
ccRCC cells and whether downregulation of PP5 activates the
intrinsic or extrinsic apoptotic pathway. These findings could
ultimately have therapeutic implications.
EXPERIMENTAL PROCEDURES
Plasmids, Yeast Strains, and Yeast Growth Media
Detailed methodologies, a list of primers (Table S2), and media conditions for
both yeast and mammalian cells are provided in Supplemental Experimental
Procedures.
Analysis of Human ccRCC Tumors
Tumor and adjacent normal tissues of patients with conventional ccRCC were
obtained with written informed consent from the Department of Urology at
SUNY Upstate Medical University and approved by the institutional review
board. Because each patient’s identity was kept confidential, information on
gender and age was not available. At the time of radical or partial nephrec-
tomy, which was done with <10 minutes of renal ischemia, ccRCC tumors
were dissected into 8 mm3 pieces and protein was extracted and quantified
as previously described in detail (Woodford et al., 2016b). The tissues were
also stained with H&E and examined by a pathologist.
Protein Extraction, Immunoprecipitation, and Immunoblotting
Protein extraction from yeast, mammalian cells, and human tissues was car-
ried out usingmethods previously described (Mollapour et al., 2010; Woodford
et al., 2016b). Detailedmethodology is provided in Supplemental Experimental
Procedures.
In Vitro Cdc37 Dephosphorylation Assay
The rate of dephosphorylation of S13-Cdc37 by PP5 was monitored by mixing
5 mM purified phospho-S13-Cdc37 without or with 2.5 mM Hsp90a in a buffer
containing 100 mM NaCl, 50 mM Tris (pH 7.5), 2 mM DTT, and 1 mM MnCl2.
The reaction was started by adding 0.25 mM PP5 (wild-type or phosphomu-
tants or the CK1d-mediated phosphorylated form), and samples were incu-
bated at 30C. Samples were taken every 10 min for SDS-PAGE analysis.
The phosphorylation state of S13-Cdc37 was examined by immunoblotting
using a phospho-Ser13-specific antibody (Abcam).
PP5 Activity Assay with pNPP
PP5 activity was assayed in vitro using a pNPP assay as previously described
(Oberoi et al., 2016). Detailed methods are provided in Supplemental Experi-
mental Procedures.
In Vitro Ubiquitination of PP5
Detailed methods for in vitro ubiquitination of PP5 are provided in Supple-
mental Experimental Procedures.1894 Cell Reports 21, 1883–1895, November 14, 2017Annexin V/PI Apoptosis Analysis
Apoptosis was detected by Annexin V/PI immunostaining assay as described
by themanufacturer (Bio-Rad/AbD Serotec). Detailed methods are provided in
Supplemental Experimental Procedures.
MTT Assay
A498, 786-O, and Caki-1 cells were plated at 10,000 cells per well in 96-well
plates. Cells were treated with 0.1, 0.2, 0.3, 0.5, 1.0, and 2.0 mM IC261. After
72 hr, an MTT assay was performed according to the manufacturer’s protocol
(BioVision, catalog number K302-500). Detailed methodology is described in
Supplemental Experimental Procedures.
Soft Agar Colony-Formation Assay
Soft agar colony formation assay was performed similar to a previously
described method (Borowicz et al., 2014). Detailed methodology can be found
in Supplemental Experimental Procedures.
Quantification and Statistical Analysis
The data presented are representative of three biological replicates
unless otherwise specified. Data were analyzed with an unpaired t test. Aster-
isks in the figures indicate significant differences (*p < 0.05; **p < 0.005;
***p < 0.0005; ****p < 0.0001). Error bars represent the SD for three indepen-
dent experiments unless otherwise indicated.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and three tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2017.10.074.
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